RadNet, Inc., a national leader in diagnostic imaging services, has acquired See-Mode Technologies PTE LTD, a Singapore-based artificial intelligence innovator specializing in ultrasound imaging. The strategic acquisition aims to strengthen RadNet's digital health portfolio through its DeepHealth subsidiary, with a focus on improving diagnostic accuracy and workflow efficiency in thyroid and breast ultrasound examinations.

The acquisition addresses critical challenges in ultrasound imaging, where approximately 20 million thyroid and breast ultrasound exams are performed annually in the United States alone. See-Mode's AI technology automates detection and reporting processes, generating standardized reports from ultrasound images to enhance clinical workflows and diagnostic consistency.

"Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant," stated Dr. Howard Berger, President and Chief Executive Officer of RadNet.

Early implementation results have demonstrated significant operational improvements. "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers," Dr. Berger explained.

See-Mode's technology has already secured regulatory approvals in the United States, Canada, Australia, New Zealand, and Singapore. The company's AI-powered solutions analyze thyroid and breast ultrasound images, enabling clinicians to enhance both diagnostic accuracy and operational efficiency.

"Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound," said Dr. Milad Mohammadzadeh, Co-Founder of See-Mode.

The acquisition strengthens DeepHealth's comprehensive AI portfolio, which already encompasses breast, lung, prostate, and brain imaging solutions. "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth," said Kees Wesdorp, President and CEO of RadNet's Digital Health division.

RadNet plans to expand these AI-driven efficiencies beyond thyroid and breast screening to other clinical applications within its more than two million annual ultrasound studies. The enhanced offerings will also be marketed by DeepHealth to third-party organizations as part of its commercial expansion strategy. Additionally, RadNet noted that existing reimbursement codes make approximately 250,000 of its annual thyroid ultrasounds eligible for additional reimbursement, underscoring both the financial and clinical value of the enhanced technology.